权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Thyroid Follicular Cell Signaling and Development in Humans

人类甲状腺滤泡细胞信号传导和发育

基本信息

批准号：
10801642
负责人：
ANTHONY N HOLLENBERG
金额：
$ 41.25万
依托单位：
BOSTON UNIVERSITY MEDICAL CAMPUS
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-01 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10801642
关键词：
Adult Affect Anterior Area Attention BMP4 Biological Assay Birth Bone Morphogenetic Proteins Cell Line Cell Lineage Cell Therapy Cell Transplantation Cells Clone Cells Computer Models Cretinism DNA Sequence Alteration Defect Derivation procedure Development Developmental Biology Endoderm Engineering Ensure Epithelium Experimental Designs FGF2 gene Fetal Development Fibroblast Growth Factor Future Genes Genetic Processes Goals Growth Factor Health Heterozygote Hormone replacement therapy Hormone secretion Human Human Biology Hypothyroidism Immunodeficient Mouse Immunologic Deficiency Syndromes In Vitro Individual Lead Life Longevity Mediator Methodology Modeling Mus Mutation Natural regeneration Organoids Pathway interactions Patients Pluripotent Stem Cells Population Primitive foregut structure Process Production Quantitative Evaluations Rana Regenerative capacity Reporter Resolution Role Safety Signal Transduction Testing Therapeutic Thyroid Diseases Thyroid Function Tests Thyroid Gland Thyroid Hormones Thyroxine Tissues Transplantation Work cell replacement therapy cell type directed differentiation embryonic stem cell gene network gene regulatory network human disease human model in utero in vivo in vivo regeneration induced pluripotent stem cell insight molecular phenotype mutant mutation correction novel overexpression pre-clinical preclinical development progenitor reconstitution regenerative cell regenerative therapy single-cell RNA sequencing stem cell based approach stem cell technology stem cells success transcription factor volunteer

项目摘要

Project Summary The development of the thyroid gland from anterior endoderm is an essential step in development that allows for the production of thyroid hormones around week 12 in utero in humans. Unfortunately, in about 1/4000 births genetic mutations that affect this development pathway lead to congenital hypothyroidism requiring lifelong thyroid hormone replacement therapy. Thus, a better understanding of thyroid follicular cell development could lead to a process where genetic editing and cellular therapy could provide treatment for congenital hypothyroidism (CH). Our work in this area has utilized a directed differentiation approach and has identified bone morphogenic protein and fibroblast growth factor as key mediators of thyroid follicular cell lineage development across species resulting in functional murine thyroid follicular cells that can rescue athyreotic mice. In this proposal, we now turn our attention exclusively to human thyroid follicular cell development and propose three Specific Aims that will allow for the pre-clinical development of functioning human thyroid follicular cells derived from human induced pluripotent stem cells (iPSCs), In the first Aim we will utilize a novel lineage tracing methodology to understand how developing human thyroid follicular acquire their cell fate and to ensure that the process in iPSC parallels that in vivo. In the second Aim we will prove that the human thyroid follicular cells derived from iPSCs are fully able to produce thyroid hormones in vitro and can be transplanted into immunodeficient athyreotic mice to rescue their hypothyroidism. Finally, in the third Aim we will demonstrate pre- clinically that derived iPSCs from a patient with CH can be genetically corrected and re-introduced via transplant to function normally. Together completion of these Aims will provide key insight into the possibilities of iPSC derived cellular therapy for the treatment of CH and enhance our understanding of the development endodermal- derived tissues in humans.

项目摘要甲状腺从前内胚层发育是发育的重要步骤，人类在子宫内12周左右产生甲状腺激素。不幸的是，在大约1/4000的新生儿中影响这一发育途径的基因突变导致先天性甲状腺功能减退症，甲状腺激素替代疗法因此，更好地了解甲状腺滤泡细胞的发育，导致基因编辑和细胞疗法可以为先天性甲状腺功能减退症（CH）。我们在这一领域的工作利用了定向差异化方法，并确定了骨形态发生蛋白和成纤维细胞生长因子作为甲状腺滤泡细胞谱系的关键介质跨物种的发育，导致功能性鼠甲状腺滤泡细胞，可以拯救甲状腺功能不全的小鼠。在这个建议中，我们现在把我们的注意力完全转向人类甲状腺滤泡细胞的发育，并建议三个特定目标，将允许临床前开发功能性人类甲状腺滤泡细胞来源于人诱导多能干细胞（iPSC），在第一个目的中，我们将利用一种新的谱系追踪方法，方法来了解如何发展人类甲状腺滤泡获得他们的细胞命运，并确保在iPSC中的过程与在体内的过程平行。在第二个目的中，我们将证明人甲状腺滤泡细胞来自iPSC的细胞完全能够在体外产生甲状腺激素，并且可以移植到免疫缺陷型甲状腺功能不全小鼠来挽救它们的甲状腺功能减退症。最后，在第三个目标中，我们将演示预- 在临床上，来自CH患者的iPSC可以通过移植进行遗传校正和重新引入，才能正常工作这些目标的共同完成将为iPSC的可能性提供关键的见解衍生的细胞疗法治疗CH，并提高我们对发展内胚层- 人类的衍生组织。

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Regenerative therapy for hypothyroidism: Mechanisms and possibilities.

DOI：
10.1016/j.mce.2016.11.012
发表时间：
2017-04-15
期刊：
Molecular and cellular endocrinology
影响因子：
4.1
作者：
Hollenberg AN;Choi J;Serra M;Kotton DN
通讯作者：
Kotton DN

Derivation of Thyroid Follicular Cells From Pluripotent Stem Cells: Insights From Development and Implications for Regenerative Medicine.

DOI：
10.3389/fendo.2021.666565
发表时间：
2021
期刊：
Frontiers in endocrinology
影响因子：
5.2
作者：
Posabella A;Alber AB;Undeutsch HJ;Droeser RA;Hollenberg AN;Ikonomou L;Kotton DN
通讯作者：
Kotton DN